0001636050-19-000085.txt : 20190924 0001636050-19-000085.hdr.sgml : 20190924 20190924171515 ACCESSION NUMBER: 0001636050-19-000085 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190921 FILED AS OF DATE: 20190924 DATE AS OF CHANGE: 20190924 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nassif David W. CENTRAL INDEX KEY: 0001636975 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37418 FILM NUMBER: 191111495 MAIL ADDRESS: STREET 1: C/O STEADYMED THERAPEUTICS, INC. STREET 2: 2410 CAMINO RAMON CITY: SAN RAMON STATE: CA ZIP: 94583 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Axovant Gene Therapies Ltd. CENTRAL INDEX KEY: 0001636050 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981333697 FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 11-12 ST. JAMES'S SQUARE STREET 2: SUITE 1, 3RD FLOOR CITY: LONDON STATE: X0 ZIP: SW1Y 4LB BUSINESS PHONE: 44 203 318 9708 MAIL ADDRESS: STREET 1: 11 TIMES SQUARE STREET 2: 33RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Axovant Sciences Ltd. DATE OF NAME CHANGE: 20150324 FORMER COMPANY: FORMER CONFORMED NAME: Axovant Sciences, Inc. DATE OF NAME CHANGE: 20150324 FORMER COMPANY: FORMER CONFORMED NAME: Roivant Neurosciences Ltd. DATE OF NAME CHANGE: 20150309 4 1 wf-form4_156935969903570.xml FORM 4 X0306 4 2019-09-21 0 0001636050 Axovant Gene Therapies Ltd. AXGT 0001636975 Nassif David W. C/O AXOVANT GENE THERAPIES LTD., 11 TIMES SQUARE, 33RD FLOOR NEW YORK NY 10036 0 1 0 0 Principal Financial Officer Restricted Stock Units 2019-09-21 4 A 0 30120 0 A Common Shares 30120.0 30120 D Each restricted stock unit represents the right to receive one share of the Issuer's common stock. 50% of the common shares underlying the restricted stock units vest on January 31, 2020 and the remainder vest on July 31, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such date. /s/ David W. Nassif 2019-09-24